NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) announced that NEREUS™ (tradipitant), described as the first new U.S. prescription treatment in 47 years for prevention of vomiting induced by motion, will sponsor the No. 47 Rahal Letterman Lanigan Racing entry in the NTT IndyCar Series. The 2026 partnership highlights NEREUS™ as a selective NK-1 receptor antagonist and will feature prominent NEREUS™ branding on the No. 47 IndyCar at select series events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Market Context

The stock is up +8.0% following this news. If a sharp rally followed this sponsorship news, it would...

Analysis

The stock is up +8.0% following this news. If a sharp rally followed this sponsorship news, it would extend the pattern seen when NEREUS’ U.S. launch previously coincided with a 8% gain. However, Vanda’s effective S-3 shelf for up to $200,000,000 of securities leaves room for future capital-raising risk.

Key Figures

Gap since last treatment: 47 years Sponsored car number: No. 47

2 metrics

Gap since last treatment 47 years Time since last new U.S. motion sickness treatment

Sponsored car number No. 47 NTT IndyCar Series entry sponsored by NEREUS

Historical Context

5 past events · Latest: Jul 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 07	Regulatory designation	Positive	+3.0%	FDA Rare Pediatric Disease Designation for CMT2S therapy VCA-894A.
May 27	Regulatory designation	Positive	+3.9%	Japan orphan drug designation for imsidolimab in generalized pustular psoriasis.
May 07	Investor conferences	Neutral	-1.7%	Planned participation in three May 2026 health care investor conferences.
May 06	Earnings report	Neutral	-14.1%	Q1 2026 results with NEREUS launch and raised full-year revenue guidance.
May 04	Product launch	Positive	+8.0%	U.S. commercial availability of NEREUS for motion-induced vomiting prevention.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent regulatory designations and the NEREUS launch have coincided with positive 1-day moves, while other corporate updates have seen more mixed trading.

Key Terms

nk-1 receptor antagonist

1 terms

nk-1 receptor antagonist medical

"a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion"

A NK-1 receptor antagonist is a type of medicine that blocks a specific cell receptor in the brain and body that normally responds to a signaling molecule called substance P; by blocking that signal, these drugs can reduce severe nausea and vomiting and can affect pain and inflammation. For investors, the term signals a drug class with clear clinical use and regulatory pathways, patent and market opportunities tied to oncology supportive care and other indications, and trial outcomes that can strongly influence commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

The partnership aligns NEREUS'™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.

This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in the United States. NEREUS™ represents a modern advancement as a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion, offering a new option for millions who experience motion sickness during travel.

"Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda. 

The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.

About NEREUS™ (tradipitant)

NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Rahal Letterman Lanigan Racing

Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What did Vanda Pharmaceuticals (VNDA) announce about NEREUS™ and IndyCar on July 15, 2026?

Vanda announced that NEREUS™ will sponsor the No. 47 Rahal Letterman Lanigan Racing IndyCar entry in 2026. According to Vanda, the NEREUS™-branded car will feature prominent visibility across select NTT IndyCar Series events.

What is NEREUS™ (tradipitant) and how is it described by Vanda Pharmaceuticals (VNDA)?

NEREUS™ is described as a selective NK-1 receptor antagonist prescription medication to prevent vomiting induced by motion. According to Vanda, it is the first new U.S. prescription treatment for this purpose in 47 years, offering a modern option for motion sickness sufferers.

Why is the No. 47 IndyCar significant for NEREUS™ and Vanda Pharmaceuticals (VNDA)?

The No. 47 car marks 47 years since the last new U.S. motion sickness treatment was introduced. According to Vanda, sponsoring the No. 47 entry symbolizes this historical gap and highlights NEREUS™ as a new preventive option for motion-induced vomiting.

Which racing team is NEREUS™ partnering with for its IndyCar sponsorship in 2026?

NEREUS™ is partnering with Rahal Letterman Lanigan Racing to sponsor the No. 47 IndyCar in the NTT IndyCar Series. According to Vanda, this collaboration links NEREUS™ motion relief with IndyCar’s high-speed, focus-intensive environment.

At which events will the NEREUS™-branded No. 47 IndyCar appear in the 2026 NTT IndyCar Series?

The NEREUS™-branded No. 47 IndyCar will appear at select 2026 NTT IndyCar Series events. According to Vanda, the sponsorship provides prominent NEREUS™ visibility, though specific race dates and locations were not disclosed in the announcement.

How does Vanda Pharmaceuticals (VNDA) position NEREUS™ in the motion sickness treatment landscape?

Vanda positions NEREUS™ as a modern advancement in motion sickness care, focused on preventing vomiting induced by motion. According to Vanda, it offers a new prescription option for millions who experience motion sickness during travel in the United States.